Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

3 of 6
BACK NEXT
Abbott Laboratories
Abbott Laboratories

The drug and medical device maker recently received FDA approval for cholesterol drug Simcor, which could be a worthy contender for Vytorin, a drug created by rivals Merck and Schering-Plough.

And sales of Abbott's important Humira arthritis drug grew 42% over the fourth quarter, a good sign for the company. JPMorgan analyst Michael Weinstein thinks Abbott is worth buying. He expects earnings to grow 14% in 2008.

Abbott currently trades at about 17 times 2008 estimates and offers a dividend yield of 2.6%. And Abbott's dividend has increased 7% annually, on average, over the past five years. To put that in perspective, rivals such as Merck, Wyeth have boosted their payouts to investors by just 1% and 4% on average over the past few years.



NEXT: Federated Investors
Last updated June 20 2008: 1:23 PM ET
More Galleries
World's Top Employers for New Grads For an exclusive CNNMoney list, research firm Universum Global surveyed business students at colleges around the world to see where they most want to work. More
Brexit voices: In or out? CNNMoney speaks to British people to find out their views ahead of the referendum on EU membership. More
10 key facts about the U.S. economy Unemployment is down, gas is cheap and America is growing. But just how strong is it? More

Special Offer